Merck’s investigational zilovertamab vedotin in combination with R-CHP demonstrates complete response rate of 100% at 1.75 mg/kg dose in phase 2 trial of previously untreated patients with Diffuse Large B-Cell Lymphoma

CAR-T Digest - August 2020

Weekly Digest - December 2024

08 Dec 2024: Merck’s investigational zilovertamab vedotin in combination with R-CHP demonstrates complete response rate of 100% at 1.75 mg/kg dose in phase 2 trial of previously untreated patients with diffuse large B-cell lymphoma

Merck presented data from the Phase 2 waveLINE-007 trial of zilovertamab vedotin, an investigational ADC targeting ROR1, combined with R-CHP for treating previously untreated diffuse large B-cell lymphoma (DLBCL)
The trial showed a 100% complete response (CR) rate in 15 patients treated with zilovertamab vedotin at a 1.75 mg/kg dose
The 1.75 mg/kg dose has been established as the recommended dose for the Phase 3 trial of this investigational ADC
Approximately 40% of DLBCL patients experience relapsed or refractory disease after standard first-line treatment, highlighting the need for new treatment options
Merck emphasized the promising response rate and manageable safety profile of zilovertamab vedotin, expressing optimism for its potential in treating hematologic malignancies